A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
London's got Chemistry (biology and physics too)
24 May 2013
With the development of two new £1 billion research parks and a host of world class superboffins working here, the capital is at the nucleus of a serious science explosion. Joshi Herrmann distils the data.
Professor Stephen Caddick, Vice-Provost (Enterprise) comments.